94 related articles for article (PubMed ID: 23545664)
21. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
Bobrie G;
Clin Ther; 2012 Aug; 34(8):1705-19. PubMed ID: 22853848
[TBL] [Abstract][Full Text] [Related]
22. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
[TBL] [Abstract][Full Text] [Related]
23. Effect of single-pill irbesartan/amlodipine combination-based therapy on clinic and home blood pressure profiles in hypertension with chronic kidney diseases.
Kobayashi R; Tamura K; Wakui H; Ohsawa M; Azushima K; Haku S; Uneda K; Ohki K; Haruhara K; Kinguchi S; Umemura S
Clin Exp Hypertens; 2016; 38(8):744-750. PubMed ID: 27936999
[TBL] [Abstract][Full Text] [Related]
24. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
[TBL] [Abstract][Full Text] [Related]
25. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
[TBL] [Abstract][Full Text] [Related]
26. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
Mallion JM; Heagerty A; Laeis P
J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
[TBL] [Abstract][Full Text] [Related]
27. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension.
Hazan L; Hernández Rodriguez OA; Bhorat AE; Miyazaki K; Tao B; Heyrman R;
Hypertension; 2010 Jun; 55(6):1323-30. PubMed ID: 20385971
[TBL] [Abstract][Full Text] [Related]
28. CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients.
Chen G; Jiang S; Mao G; Zhang S; Hong X; Tang G; Li Z; Liu X; Zhang Y; Xing H; Wang B; Yu Y; Xu X
Methods Find Exp Clin Pharmacol; 2006; 28(1):19-24. PubMed ID: 16541193
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
Neutel JM; Franklin SS; Bhaumik A; Lapuerta P; Oparil S
Clin Exp Hypertens; 2009 Oct; 31(7):572-84. PubMed ID: 19886855
[TBL] [Abstract][Full Text] [Related]
30. Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.
Shimoura H; Tanaka H; Matsumoto K; Mochizuki Y; Hatani Y; Hatazawa K; Matsuzoe H; Ooka J; Sano H; Sawa T; Motoji Y; Ryo-Koriyama K; Hirata KI
Heart Vessels; 2017 May; 32(5):584-590. PubMed ID: 27722772
[TBL] [Abstract][Full Text] [Related]
31. Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.
Divchev D; Grothusen C; Luchtefeld M; Thoenes M; Onono F; Koch R; Drexler H; Schieffer B
Eur Heart J; 2008 Aug; 29(16):1956-65. PubMed ID: 18565968
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
Omboni S; Malacco E; Napoli C; Modesti PA; Manolis A; Parati G; Agabiti-Rosei E; Borghi C
Adv Ther; 2017 Apr; 34(4):784-798. PubMed ID: 28260186
[TBL] [Abstract][Full Text] [Related]
33. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
Uzui H; Morishita T; Nakano A; Amaya N; Fukuoka Y; Ishida K; Arakawa K; Lee JD; Tada H
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):304-9. PubMed ID: 24288395
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender.
Asmar R; Oparil S
Clin Exp Hypertens; 2010; 32(8):499-503. PubMed ID: 21091220
[TBL] [Abstract][Full Text] [Related]
35. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
Schmieder RE; Krekler M
MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
[TBL] [Abstract][Full Text] [Related]
36. Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats.
Hasegawa Y; Nakagawa T; Uekawa K; Ma M; Lin B; Kusaka H; Katayama T; Sueta D; Toyama K; Koibuchi N; Kim-Mitsuyama S
Transl Stroke Res; 2016 Feb; 7(1):79-87. PubMed ID: 25533877
[TBL] [Abstract][Full Text] [Related]
37. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.
Stumpe KO; Agabiti-Rosei E; Zielinski T; Schremmer D; Scholze J; Laeis P; Schwandt P; Ludwig M;
Ther Adv Cardiovasc Dis; 2007 Dec; 1(2):97-106. PubMed ID: 19124398
[TBL] [Abstract][Full Text] [Related]
38. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.
Schepke M; Wiest R; Flacke S; Heller J; Stoffel-Wagner B; Herold T; Ghauri M; Sauerbruch T
Am J Gastroenterol; 2008 May; 103(5):1152-8. PubMed ID: 18422814
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension.
Smolensky MH; Hermida RC; Portaluppi F
Chronobiol Int; 2007; 24(1):171-81. PubMed ID: 17364587
[TBL] [Abstract][Full Text] [Related]
40. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.
Fliser D; Wagner KK; Loos A; Tsikas D; Haller H
J Am Soc Nephrol; 2005 Apr; 16(4):1135-40. PubMed ID: 15716329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
